177Lu-PSMA (PluvictoR) is a promising new radiopharmaceutical that could be a game-changer for patients with advanced metastatic prostate cancer. Duke's Division of Nuclear Medicine and Radiotheranostics was one of the first programs in the US to offer this treatment in June 2022 and continues to be a leader in this field. On March 15, 2023, our radiotheranostics team celebrated our 300th administration of 177Lu-PSMA.